An Inside Look At Site Centricity in Clinical Trials
Add bookmark
We respect your privacy, by clicking "Download Your Copy" you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest subject to their privacy policy. You have the right to object. In addition, you will receive our e-newsletter, including information on related online learning opportunities. For further information on how we process and monitor your personal data, and information about your privacy and opt-out rights, click here.
With the expanding global spread of clinical trials, the trial supply arena has shifted in focus towards the advantages of site centricity. Here, the enhancement of clinical trial supply is propelled by the sites’ perspective. Closer collaboration and feedback from sites assists with overcoming various operational challenges in clinical trials.
Some have advanced to test fully site centric models. The rise of telemedicine has opened the horizons for teams to run with these ‘hub and spoke models’ 1 This set-up involves trained physicians engaging with patients in local community health clinics, monitoring them remotely and collecting data using telemedicine technology. This strategy reduces the amount of specialists needed and has numerous cost and efficiency benefits in comparison to deploying a range of medical centers.
Pharma IQ speaks to Dr Samantha Carmichael, Lead Pharmacist Clinical Trials of NHS Greater Glasgow & Clyde and Mandy Wan, Lead Paediatric Research Pharmacist, Evelina London Children’s Hospital in regards to the growing culture of site centricity in today’s clinical trials.
[inlinead]
 | Have Your Say Rate this feature and give us your feedback in the comments section below |
